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Abstract
Background: The management of patients with recurrent gynecological malignancy is complex, and often
contentious. While historically, patients with metastases in the lungs, liver or brain have been treated with
palliative intent, surgery is proving to have an increasing role in the management of such patients.
Methods: In this review article, the surgical management of lung, liver and brain metastases from gynecological
cancers is examined. A search of the English language literature over the last 25 years was conducted using the
Medline and PubMed databases.
Results: The results for management of metastases from the endometrium, ovary and cervix to the lung, brain and
liver show that surprisingly good long-term survival results can be achieved for resection of metastases from all three
organs. Patient selection is critical, and surgery is often used in conjunction with other treatment modalities.
Conclusions: From this review, it is apparent that surgery should play an increasing role in the management
of patients with parenchymal metastases from gynecological cancers. The surgery should ideally be performed
in high volume, tertiary centers where there is a committed multi-disciplinary team with the necessary infrastructure to
achieve the best possible outcomes in terms of both survival and morbidity.
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Background
The primary management of patients with a gynecological
malignancy is usually protocol driven, and is seldom con-
troversial, but the management of patients with recurrent
disease is often contentious. It requires a multidisciplinary
team discussion, and complex decisions around the pos-
sible roles of surgery, chemotherapy, radiation therapy or
hormonal therapy. Often, a combination of therapies will
be required.
Historically, patients with metastases in the lungs, liver
or brain have been treated with palliative intent. Surgery
is proving to have an increasing role in the management
of such patients, and survivals are surprisingly good in
many cases.
We undertook a search of the English literature
over the past 25 years to seek references to the surgi-
cal management of lung, liver or brain metastases
from cancers of the endometrium, ovary or cervix.
The MEDLINE/PubMed database was searched, using
the keywords metastases, lungs, liver, brain, endomet-
rium, ovary and cervix.
Surgical management of lung metastases
The first successful lobectomy for lung metastases in the
20th century was reported by Barney and Churchill in
1939 [1]. The patient was a 55-year old woman with a
metastatic renal cell carcinoma, and she survived
disease-free for 23 years Subsequently, there have been a
number of reports of pulmonary metastasectomy for a
variety of tumors [2–8], and the commonest primary
epithelial tumour sites have been the colon, rectum,
kidney and breast [9].
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Endometrial cancer is the commonest gynecological
cancer in Western countries, and the majority of pa-
tients are diagnosed with disease confined to the corpus
[10]. The lungs are the commonest site of hematogenous
spread for patients with advanced endometrial cancer
[11, 12], but lung metastasis may occasionally occur with
very early stage disease [13].
The commonest gynaecological cancer in developing
countries is cervical cancer [14]. A review of the records
of 2075 Sri Lankan women treated for cervical cancer
from 1989 to 1993 reported that 38 patients (1.8 %) de-
veloped lung metastases, with a median interval from
diagnosis of 9 months [15].
Diagnosis
Most recurrences in the lungs are diagnosed by the in-
vestigation of symptoms, or of rising CA125 titers in the
case of ovarian cancer. Barter et al. reported that there
was no indication for routine chest x-ray in the follow-
up of patients with cervical cancer, as there was no sig-
nificant survival difference between symptomatic and
asymptomatic patients [16].
Imaging
Thoracic metastases from gynecologic malignancies ex-
hibit various imaging patterns [17]. Metastases from
endometrial cancer typically manifest as pulmonary nod-
ules and lymphadenopathy, whereas ovarian cancer often
manifests with small pleural effusions and subtle pleural
nodules. Most squamous cervical carcinomas manifest
as solid pulmonary nodules, but cavitation occurs rea-
sonably frequently. A “halo sign” is sometimes seen in
hemorrhagic metastatic choriocarcinoma. Metastases
from common gynecologic malignancies may be subtle
and mimic benign condition such as intrapulmonary
lymph nodes or granulomatous disease [17]. If a solitary
lung lesion is found, it is always important to consider
the possibility of primary lung cancer.
The spiral computed tomographic (CT) scan has rev-
olutionized the identification of small lung metastases.
Before the advent of spiral CT technology, bimanual
palpation of the lung through an open thoracotomy or
sternotomy was considered necessary to avoid missing
small lesions [9]. The spiral CT scan has allowed better
characterisation of both location and resectability of
pulmonary nodules, so minimally invasive surgery has
become a more attractive option [18].
A preoperative PET/CT is desirable to exclude disease
beyond the lungs, which would make pulmonary resec-
tion inadvisable in most cases.
Indications for pulmonary metastasectomy
Specific criteria vary considerably in the literature.
Clearly, there needs to be an adequate pulmonary
reserve, and a limited number of lung metastases. A soli-
tary metastasis is ideal, and 2 papers have reported a
100 % 5-year survival for a total of 21 patients with a
solitary endometrial lung metastasis treated with wedge
resection and adjuvant hormonal therapy [11, 19]. The
estrogen and progesterone receptor (ER/PR) status
should be obtained at the time of metastacectomy for
endometrial cancer [20].
Except for patients with ovarian cancer, whose tumors
are often quite sensitive to chemotherapy or targeted ther-
apy, it is preferable to have no spread beyond the thorax. A
disease-free interval of at least 12, but preferably 24 months,
is an important prognostic factor [9, 19, 21–23].
Surgical technique
The operative procedure of choice is a wedge resection.
Seki et al. stated that this should be performed with a
disease-free margin of at least 2 cm for patients with
metastatic lesions smaller than 3 cm diameter. Lobec-
tomy was recommended for lesions larger than 3 cm,
because of the greater risk of microscopic satellite le-
sions [24].
Although most reports are of open thoracotomies,
video-assisted thoracic surgery (VATS) has recently be-
come an accepted and often preferred modality in pa-
tients with a limited number of metastases, either
unilateral or bilateral [18]. It is usually associated with a
shorter hospital stay, and preserves the ability of the pa-
tient to undergo repeated resections, which may be ne-
cessary to achieve cure [9].
Mediastinal lymphadenectomy was recommended by
Seki et al. for metastatic squamous cell carcinomas 3 cm
or more in diameter [24]. In the paper from the Mayo
clinic, there was no association between lymphadenec-
tomy and survival, but the number of positive nodes was
small [23]. On the evidence available, resection of at
least bulky nodes only would seem to be a reasonable
option.
Reported series
The findings of reported series with 5 or more patients
are summarised in Table 1. Although small series had
been reported earlier [2, 25, 26], the first major report of
resection of pulmonary metastases from a gynecological
cancer came from Memorial Sloan Kettering Cancer
Center in 1992 [27]. The study involved 45 patients
whose pulmonary metastases from uterine sarcomas
were resected between 1960 and 1989. All patients had a
prior hysterectomy for uterine sarcoma, no extrathoracic
tumor, and disease that was thought to be resectable.
The mean age of the patients was 50 years, and the
mean interval from hysterectomy to thoracotomy was
44 months (range 1 to 193 months).
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reporting suCervical – 60.9 %
Endometrial – 17.4 %
Ovarian – 21.7 %
1 nodule – 69.6 %
2–3 nodules – 30.4 %




Cervical – 61 %
Endometrial – 100 %
Ovarian – 100 %
Recurrence – 43.4 %
Univariate analysis – positive







27 Uterine and cervical cancer 1 metastasis – 66.7 %
2 metastases – 18.5 %
≥2 metastases – 14.8 %
Surgical approach:
- thoracotomy – 81.5 %
- sequential bilateral – 7.4 %
- unilateral VATS – 3.7 %
- sequential bilateral VATS – 3.7 %
- VATS + thoracotomy – 3.7 %
Lung resection:
- Wedge resection – 81.5 %
- Lobectomy – 11.1 %
- Other – 7.4 %
Second surgery for metastases
- 18.5 %
Median survival from diagnosis
of metastases – 94 months
5-year OS after diagnosis of
metastases – 84.1 %
Overall relapse rate 44 %
Positive prognostic factors
Primary site – endometrial
vs cervical (P = 0.023)




Included male and female
patients
Leiomyosarcoma – 31 cases
(38 %) - 24 pts (77 %) of
these were female
In female pts, uterus most
common primary site
Solitary metastases –
16 pts (52 %)
Bilateral disease – 19 %
- Wedge resection – 71 %
- Lobectomy – 23 %
- Segmentectomy – 6 %
- VATS – 58 %
5 year survival:
- Leiomyosarcoma – 52 %






DFI >12 months from time
of primary tumour resection
Lim [90]
2010
21 Primary and recurrent
cervical cancer
Not reported 23 resections in 21 patients
- thorocatomies – 43.5 %
- VATS – 52.2 %
- VATS following thoracotomies
– 4.3 %
Procedures – 49
- wedge resections – 51.1 %
- lobectomies – 18.4 %
- mediastinal LN dissections – 24.5 %
- segmentectomy – 2.0 %
- diaphragmatic resection −2.0 %
- pleurectomy – 2.0 %
Note – only 14 patients had
recurrent cervical cancer, and
1 patient had primary lung
cancer and mediastinal LN
metastasis from cervical cancer
Median f/up 16 months
(range 2–67)
- 2 pts died of disease
- 3 pts alive with disease




70 Uterine corpus – 52.9 %
Endometrium – 32.9 %
Cervix – 10.0 %
Ovaries – 2.9 %
Vagina – 1.3 %
Histopathology:
Leiomyosarcoma – 41.4 %
Adenocarcinoma – 32.9 %
Median number of lung
metastases – 2 (range
1–19)
Wedge excision – 63 %
Lobectomy – 20 %
Bilobectomy – 3 %
Pneumonectomy – 2.5 %
Combination – 12.5 %
5-year OS 46.8 % (95 % CI
34.2-63.0 %)




DFI between 1st gynecologic
procedure and pulmonary
resection <24 months (p = 0.004)

















Table 1 Major series reporting surgical management of pulmonary metastases from gynaecological malignancies (Continued)
Other sarcoma – 15.7 %
SCC −7.1 %
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Cervical cancer (Stage Ib or






Wedge resection – 27.6 %
Segmentectomy – 6.9 %
Lobectomy – 65.5 %
Hilar or mediastinal lymph node
dissection – 55.2 %
5 year DFS after pulmonary









SCC – 43.6 %
Cervical adenocarcinoma – 9.8 %
Endometrial adenocarcinoma – 17.3 %
Choriocarcinoma – 12.0 %
Leiomyosarcoma – 4.7 %
Solitary metastasis
−58 %
2–3 mets – 23 %
≥4 mets – 17
%
Wedge resection – 50 %
Lobectomy – 45 %
Bilobectomy – 2.5 %
Pneumonectomy – 2.5 %
Overall survival after surgical
resection:
5-year – 54.6 %
10-year – 44.9 %
5-year survival by
histpathological type:
SCC – 46.8 %
Cervical adenoca – 40.3 %
Endometrial adenoca – 75.7 %
Choriocarcinoma – 86.5 %
Leiomyosarcoma – 37.9 %
Univariate analysis – negative
prognostic factors:
Primary tumour in cervix
DFI <12 months
Resection≥ 4 mets
Large tumour size (≥3 cm)
Multivariate analysis:









Uterine – 73.2 %
Cervical – 26.8 %
Patients undergoing resection:
Uterine – 76.0 %
Cervical – 24.0 %
Solitary – 28 %
Multiple – 72 %
Uterine:
- Wedge – 63.1 %
- Lobectomy – 10.5 %
- Lobectomy/wedge
– 15.8 %
- Bilobectomy – 5.3 %
- Segmentectomy – 5.3 %
Cervix:
- Wedge – 66.7 %
- Lobectomy – 33.3 %
Uterine cancer
- median survival 26 months




- median survival 36 months
Uterine cancer – favourable
prognostic factors:
Leiomyosarcoma vs





- Leiomyosarcoma – 84 %
- Endometrial stromal
sarcoma – 9 %
- Mesodermal mixed
tumours – 7 %
Unilateral lesions
– 71 %
1 lesion – 51 %
Nodules >2 cm – 70 %
Staged thoracotomies
– 100 %
Median sternotomy and bilateral
resections – 4.4 %
Incomplete resection
– 36 %
From time of pulmonary
resection:
- 5 year survival – 43 %
- 10 year survival – 35 %
Median follow-up – 89 months
Disease recurrence – 42 %
Significant predictors:




- number of metastases
- disease free interval
- patient age

















All gross disease could be resected in 29 patients
(64 %), the vast majority by wedge resection. The post-
operative mortality was 2 % (one patient). The 5- and
10-year survival from the time of the pulmonary resec-
tion was 43 % and 35 % respectively, with a mean
follow-up of 25 months. The mean survival for patients
with bilateral disease was 27 months, while it was
39 months for patients with unilateral disease (p = 0.02).
A more recent paper looked at 82 male and female
patients who underwent pulmonary resection for
metastatic sarcoma with curative intent at the Brigham
and Women’s Hospital from 1989 to 2004 [22]. Leiomyo-
sarcomas accounted for 31 cases (38 %), and 77 %
of leiomyosarcomas were in females. Patients with
leiomyosarcomas had a better overall survival than
patients with other sarcoma subtypes (70 versus
24 months; p = 0.049). Disease-free survival of greater
than 12 months from time of primary tumor resec-
tion was the only significant prognostic factor in
multivariate analysis. Systemic chemotherapy had no
significant effect on long term survival.
In 2004, the Metastatic Lung Tumor Study Group of
Japan reported the results of the largest series of patients
having pulmonary metastasectomy for uterine malignan-
cies. They reported on 133 patients undergoing surgery
between March 1984 and February 2002 [21]. The
postoperative mortality was 0.8 % (1 case). The only
significant prognostic factor in multivariate analysis was
a disease-free interval of less than 12 months [21].
Another Japanese study published in 2004 evaluated
the role of resection of pulmonary metastases from
patients with stage Ib or II cervical cancer who
underwent curative initial treatment [28]. The 5-year
disease-free survival was 42 % for patients with one
or two metastases, compared to 0 % for patients with
three or four (p = 0.0003). Patients with squamous cancers
had a 5-year disease-free survival of 47.4 %, compared to
0 % for patients with glandular cancers (p = 0.014)
A large series of surgical resections for lung metastases
from gynaecological malignancies was reported from the
Mayo Clinic in 2006 [23]. They reported 70 patients
with metastatic disease limited to the lungs who were
treated between 1985 and 2001. Synchronous lung me-
tastases were present in 9 patients (13 %). Post-operative
morbidity occurred in 18 patients (26 %), and there was
one postoperative death (1.4 %) [23]. The overall survival
for the group was 47 % at 5 years and 34 % at 10 years.
The most recent report was from Nagoya University
Hospital in 2015 [29]. They reviewed 37 patients with
isolated lung metastases (<3 nodules). They compared
23 patients who underwent surgical resection (cervical
(14), endometrial (4) or ovarian (5) carcinomas), with 10
patients who underwent chemotherapy only. Among 6
patients who recurred in the lung a second time, 5
underwent a second pulmonary metastasectomy and all
5 patients were alive and well at the time of reporting.
There was no significant difference in overall survival
between patients having surgery or chemotherapy, but
the numbers were small and the trend favoured surgery
(81.7 % versus 49.5 %; p = 0.072). There was a significant
survival advantage for patients with a disease-free sur-
vival of > 24 months (p =0.006).
Surgical management of brain metastases
Brain metastases are common with breast, lung, and
renal carcinomas, and malignant melanoma [30, 31], but
are rare with gynaecological cancers, with the exception
of choriocarcinoma [32, 33]. They are usually associated
with widely disseminated disease.
Diagnosis
Symptoms of brain metastases may be subtle initially,
and may include headaches, nausea, vomiting, confusion,
dizziness, decreased mental status, general or extremity
weakness, urinary incontinence, gait disturbance, ataxia,
visual disturbance including diplopia, photophobia,
speech impairment, syncope or seizures [32–36]. In-
creased intracranial pressure caused by associated brain
edema leads to the development of papilledema in the
fundus of the eye, which is a classical sign of a brain
tumor [37].
Imaging
Most brain metastases are diagnosed with a computed
tomographic (CT) scan of the brain, which has been per-
formed to investigate suspicious symptoms. The metas-
tasis appears as a heterogeneous, contrast enhancing
lesion [35] (Fig. 1). Metastatic ovarian cancers can occa-
sionally be calcified [38]. Contrast-enhanced magnetic
resonance imaging (MRI) is the most accurate modality
to image the brain [39].
Surgical Technique
Traditionally, patients with solitary metastases have
undergone metastasectomy and whole brain radiother-
apy (WBRT) [37, 39]. The latter is associated with a
number of late complications, including brain atrophy,
necrosis, dementia, and endocrine dysfunction [40].
More recently, stereotactic radiosurgery using a
“gamma-knife” (GKRT) has become available [37, 41, 42].
This is a technique that enables the precise delivery of a
high-dose of gamma radiation to a small intracranial tar-
get, while sparing the surrounding normal brain. If there
is a solitary lesion, surgical resection followed by GKRT to
the tumor bed is ideal. GKRT offers an advantage if the le-
sion is inaccessible. Lesions larger than 3 cm are less likely
to be controlled by GKRT [41].
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Indications for surgical resection
Ideally, suitable patients for brain metastasectomy
would have a solitary lesion and no evidence of extra-
cranial disease [35, 43–45]. Such patients are uncom-
mon, as the majority of patients have multiple brain
metastases [39, 46–49]. A well controlled primary
tumor [42, 50] and a disease-free interval of at least
12 months is desirable, but Petru et al. reported a patient
who had a solitary brain metastasis diagnosed prior to the
diagnosis of endometrial cancer. She had stereotactic ra-
diosurgery to the brain lesion, followed by aggressive
cytoreductive surgery and doxorubin-based chemotherapy
for the primary tumor, and remained alive and free of dis-
ease at 171 months [51].
Brain metastases by primary site
There have been comprehensive reviews by Piura and
Piura regarding brain metastases from gynaecological
cancers [32, 33, 37]. The incidence, pattern of brain me-
tastasis, and survival by primary site are summarised in
Tables 2 and 3.
Ovarian cancer
Of the gynaecological cancers, ovarian cancer is associ-
ated with the highest incidence of brain metastases, and
there have been two comprehensive reviews in the past
5 years. In 2011, Piura and Piura reported 521 cases be-
tween 1978 and 2011 [32], while in 2014, Pakneshan et
al. reported 591 cases between 1978 and 2013 [45]. Piura
and Piura determined the incidence of brain metastases
from ovarian cancer to be 1.2 % [32], which was twice
the incidence associated with cervical [37] or endomet-
rial cancer [33]. Pakneshan et al. reported that the inci-
dence among the various studies ranged from 0.49 to
11.4 %, with an average of 2.55 % [45]. A review of the
literature reveals several case reports and small series,
the largest being 72 patients [47].
Since the advent of chemotherapy over 50 years ago,
the incidence of brain metastases from ovarian cancer
has increased, presumably because these patients are liv-
ing longer, and because the chemotherapy has difficulty
crossing the blood–brain barrier [31]. A review of 3,690
patients with epithelial ovarian cancer treated at the
Royal Marsden Hospital from 1980 to 2000 reported
that the incidence of brain metastases increased from
0.2 % in 1980–84 to 1.3 % in 1995–99 (p < 0.001) [34].
Most patients have advanced stage, high-grade serous
cancers at initial presentation [35, 45, 47, 48, 52–54],
and the brain metastasis often follows a negative
second-look laparotomy [54–56]. CA125 titers are not
absolutely reliable in the screening for brain metastases
[57], although they are elevated in the majority of pa-
tients [45, 46].
In the review by Piura and Piura, the median interval
from diagnosis to brain metastasis in 31 series was
24.3 months (range 11 to 46 months) [32], although
there was a case report of a patient who developed a
brain metastasis 11 years after diagnosis of the primary
cancer [58]. The disease was confined to the central ner-
vous system in 236 of 504 patients (46.8 %) [32]. The
brain parenchyma, most commonly the cerebrum, was
the site of metastasis in 489 patients (97 %) and the
leptomeninges in 15 cases (3 %). Most brain metastases
were multiple (269 of 474; 56.8 %) [32].
Prognosis
Survival by treatment type in patients with brain metas-
tases from ovarian cancer is summarised in Table 4.
Surgical resection significantly improved the survival
Fig. 1 CT scan of the brain showing a solitary metastasis, 5x4 cm, in
the right occipital lobe, with some extension to the parietal lobe. Note
the heterogeneic appearance of the metastasis and the surrounding
brain edema
Table 2 Summary of incidence, disease-free survival, and pattern of brain metastasis [32, 33, 37]
Primary Site Incidence Median Disease-Free Interval Only site of metastatic disease Solitary metastasis
Ovarian (n = 521) 1.19 % (413/34 728) 24.3 months (11–46) 46.8 % (236/504) 41.9 % (205/489)
Endometrial (n = 115) 0.59 % (61/10 199) 17 months (2–108) 49 % (48/98) 56.8 % (50/88)
Cervical (n = 100) 0.57 % (n = 65/11 249) 18 months (0.25-105 months) 46.8 % (37/79) 50.6 % (40/79)
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compared to other methods of treatment [35, 43, 45, 47,
48, 52, 54, 59, 60]. Solitary metastases generally have a
better prognosis [35, 43, 45]. Cormio et al. reported 22
patients who had resection of a solitary metastasis [44].
They reported that extracranial disease and the time
interval between diagnosis of ovarian cancer and central
nervous system involvement were the only factors sig-
nificantly affecting survival. There were no operative
deaths, and low morbidity. The majority of patients had
complete resolution of their neurological symptoms [44].
Aggressive management of multiple metastases is jus-
tified [39, 46–49], particularly if the patient meets the
criteria for Class I of the Radiation Therapy Oncology
Group’s recursive partitioning analysis system, ie., age
< 65 years, Karnofsky score > 70, controlled primary
disease and no extracranial metastases [43]. Kawana
et al. described a patient who was initially diagnosed
with stage IVB ovarian cancer, and developed 3 brain
metastases after a disease-free interval of 27 months
[41]. She underwent surgical resection of the two ac-
cessible lesions, and then gamma-knife radiotherapy
for a third inaccessible lesion after 30Gy external
beam local radiation to the bed of the resected tumors
and the inoperable tumor. She remained disease-free at
5 years, with good quality of life [41].
In their recent literature review, Piura and Piura re-
ported that the median survival for patients having
whole brain radiation was 4.5 months, compared to
17 months for patients having surgical resection plus ra-
diation, and 20 months for the addition of chemotherapy
[32]. The outcomes for patients with brain metastases by
treatment modality are summarised in Table 4. In the re-
view by Pakneshan et al., combination surgery, radiation
and chemotherapy was associated with longer survival
than whole brain radiation alone (20.5 months versus
9.1 months; p = 0.04) [45]. Others have also stressed the
need for aggressive multimodal therapy, including adju-
vant chemotherapy [47, 52, 59–62], as the patients usu-
ally succumb to extracranial disease [63].
Long term survival is possible. Micha el al reported a patient
with a stage IIIC high-grade serous carcinoma who recurred
in the cerebellum 27 months after diagnosis, and following
primary cytoreductive surgery and platinum-based chemo-
therapy [64]. She had surgery and whole brain radiation and
was still alive and well 7 years post treatment for her brain
metastasis. McMeekin also described a 7-year survivor [60].
Cervical cancer
The most common site of distant metastases from cer-
vical cancer is the lung [65, 66]. Brain metastases are
rare. In a literature review in 2012, Piura and Piura re-
ported only 96 cases, with an incidence of 0.57 % [37].
The majority of patients had early stage disease at diag-
nosis – 42.2 % had stage IB and 36.6 % stage II – al-
though 80 % of patients had poorly differentiated (grade
3) tumors. Histologic types basically reflected those ex-
pected in the general population, although there were 3
(3.6 %) small cell neuroendocrine carcinomas [37].
The interval between primary diagnosis and brain me-
tastasis ranged from 1 week to 105 months, with a me-
dian of 18 months. The brain metastasis was part of a
disseminated recurrence in 53.2 % of patients, was soli-
tary in 50.6 %, and was located only in the cerebrum in
73 % of patients. Some authors have noted that brain
metastases from cervical cancer were rarely accompan-
ied by systemic disease, but they were commonly accom-
panied by uncontrolled local-regional disease [42, 50].
Prognosis
Based on limited data in the literature, Piura and Piura
determined that the median survival for no treatment
was 0.6 months, for whole brain radiation (WBRT)
Table 3 Summary of survival outcomes after diagnosis of brain metastases [32, 33, 37]
Primary Site Median survival (months) Surgery alone (months) WBRT (months) Surgery +WBRT (months) Multimodal Surgery + RT
+/− Chemo (months)
Ovarian 6.4 (1–28) 6.7 4.5 17 20
Endometrial 5 (0.1-171) 2.25 (1–18) 2 (0.25-17) Not available 22 (2.1-84)
Cervical 4 (0.1-72) 4 (1–7) 3 (0.1-22.6) (+/− chemo) 7.1 (1–72) (+/− chemo) SRS + other modality13.7
(5–22.5)
WBRT whole brain radiotherapy, RT radiotherapy, SRS stereotactic radiosurgery
Table 4 Ovarian cancer with brain metastases – survival by
treatment modality after diagnosis of brain metastases [32]
Treatment modality Median survival
(months)
% of patients (n)
Total = 538
WBRT* only 4.5 35 % (182)
Surgery +WBRT 17 15.2 % (79)
WBRT + chemo 9.1 13.5 % (70)
Surgery +WBRT + chemo 20 13.3 % (69)
Surgery only 6.7 5 % (26)
SRS* or GKRS* 18 3.8 % (20)
Chemo only 7.5 1.9 % (10)
Surgery + chemo Not available 1.3 % (7)
No treatment (steroids only) 1.4 11 % (57)
*WBRT whole brain radiationtherapy, SRS stereotactic radiosurgery, GKRS
gamma knife radiosurgery
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4 months, while for surgical resection followed by
WBRT it was 7.1 months. The best median survival
(13.7 months) was achieved with stereotactic radiation,
either alone or combined with another modality [37].
Robinson and Morris reported a patient with a brain
metastasis from a squamous cell carcinoma of the cervix
who remained disease free 6 years following surgical re-
section and whole brain radiation [67]. Chura et al. re-
ported 12 patients with brain metastases from cervical
cancer, 8 of whom received WBRT, but their median
survival was only 2.3 months [68].
Endometrial Cancer
Brain metastases from endometrial cancer are rare, with
Piura and Piura documenting only 115 cases from 35
published papers, with an incidence of 0.59 % [33]. The
brain metastasis was diagnosed after a median interval
of 17 months (range 2 to 108 months). In 4 patients
(4.2 %), the primary and metastatic diagnoses were made
simultaneously, and in 9 patients (9.5 %), the brain me-
tastases were detected before the primary.
In the review by Piura and Piura, 63 % of patients (50
of 79) had advanced disease at initial diagnosis, and
78.1 % (57 of 73) had poorly differentiated tumors [33].
Almost half the patients had metastases confined to the
brain (48 of 98 patients; 49 %), and 56.8 % of patients
(50 of 88) had a solitary metastasis. Site of metastasis
was available for 66 patients, of whom 48 (72.7 %) had
disease confined to the cerebellum [33]. Of the 20 pa-
tients reported by Chura et al., 8 (40 %) had a single me-
tastasis, 4 (20 %) had two, 7 (35 %) had 3 or more, and 1
patient (5 %) had leptomeningeal disease [69].
Prognosis
In the review by Piura and Piura, the overall median sur-
vival after diagnosis of brain metastasis was 5 months
(0.1 to 171 months). Patients having WBRT alone had a
median survival of 2 months (0.25-17 months) while pa-
tients having surgical resection followed by WBRT had a
median survival of 22 months (2.1-84 months) [33].
Orrru et al. reported 2 patients treated by surgical resec-
tion followed by WBRT who were alive and well at 16
and 64 months respectively [70].
Surgical management of liver metastases
The literature on liver resection for metastatic
gynecological cancer is limited. It has been estimated
that up to 50 % of patients who die of cervical, endomet-
rial or ovarian cancer will have liver metastases at aut-
opsy [71, 72], but probably only 1 - 10 % would be
suitable for liver resection [73]. Gynecologic cancers that
metastasize to the liver usually do so in the setting of
obvious regional or systemic dissemination [71, 74].
Surgical technique
Hepatic resection has evolved, with improved surgical
techniques, instrumentation, anesthesia and periopera-
tive care, and now carries a very low morbidity and mor-
tality [73, 75, 76].
Hepatic resection usually involves non-anatomical
wedge resection (Fig. 2), but anatomical resection of one
or more liver segments may also be performed [77]. Re-
section of as much as 70 % of the liver can be per-
formed, with a mortality rate of less than 5 % in major
hepatobiliary centers [77, 78]. Over the past 15 years, ra-
diofrequency ablation, usually in conjunction with surgi-
cal resection, has extended the cohort of patients with
surgically treatable disease, and helped achieve better
locoregional control [79, 80].
Indications
Liver surgery should only be considered when all other
metastatic disease is well controlled, when disease in the
liver can be completely resected, or when liver resection
is part of the achievement of optimal cytoreduction for
patients with ovarian cancer [81, 82].
Results
The findings of reported series with 5 or more patients
are summarised in Table 5.
The first study by Brunchwig in 1963 [83] reported 24
cases of hepatic lobectomy for metastatic carcinoma, 4
of whom were from the cervix or endometrium. Three
of the four died in the perioperative period, and the
fourth died of disease at 18 months..
In most large series of patients having partial hepatec-
tomy for metastatic malignancy, gynaecological cancers
represent less than 10 % of cases [73, 76, 84–86]. A
large, multi-centre French study reported that during
the 1980’s, the median number of partial hepatectomies
Fig. 2 Non-anatomical liver resection for a patient with ovarian
cancer with involvement of the liver capsule and underlying
parenchyma
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Table 5 Major series reporting surgical management of hepatic metastases from gynaecological malignancies
First Author Year
of Publication
Number of patients Primary vs
Recurrent
Disease
Primary Site Median overall survival




Kolev [91] 2014 27 Recurrent Ovary 12 months
(2–190)
Interval from primary
surgery of >24 months
(P = 0.044)
Secondary cytoreduction
to <1 cm (P = 0.014)
Neumann [82] 2012 41 Primary Ovary R0 – 42 months
R1 – 4 months
R2 – 6 months
Post operative residual
tumour mass
Roh [77] 2011 18 Recurrent Ovary 38 months
(3–78)
Less abdominal than pelvic
disease (38 vs 11 months,
P = 0.032)
Optimal cytoreduction
(40 vs 9 months, P = 0.0004)
Negative margin status of
hepatic resection
(40 vs (months, P = 0.0196
Kamel [92] 2011 52 Primary Ovary 53 months
5-year survival 41 %
Not reported
Knowles [93] 2010 5 Recurrent Endometrioid
(Ovarian or
Endometrial)
Median OS not reported
DFS range 8–66 months
Not reported
Lim [75] 2009 14 Primary Ovary 5-year PFS by Stage:
- IIIC – 25 %
- IV – 23 %
5-year OS by Stage:
- IIIC – 55 %
- IV – 51 %
Not reported
Loizzi [94] 2005 29 Primary
(Group 1) – 8
1st Recurrence
(Group 2) – 10
2nd recurrence
(Group 3) – 11
Ovary Median survival from time of
liver metastasis diagnosis:
Group 1 – 19 months
Group 2 – 24 months
Group 3 – 10 months
Cell type
Performance status
Number of hepatic lesions
Presence of other sites of
disease at time of diagnosis
of hepatic metastasis
Platinum based chemotherapy
Weitz [76] 2005 19 Recurrent Ovary – 63.2 %
Endometrium
– 21.1 %
Cervix – 10.5 %
Fallopian tube – 5.2 %
Reproductive tract tumours
(note – included testicular cancer
pts, but no difference between
ovary and testicular survival)
Median cancer specific survival
reproductive tract primary
– 115 months
Ovary - 3 year recurrence free
survival 58 %
Primary tumour type
Length of disease free interval
from primary tumour





factors for OS identified on
univariate analysis
Merideth [89] 2003 26 Recurrent Ovary Overall median disease-related
survival 26.3 months
>12 months since original
diagnosis (27.3 vs 5.7 months,
P = 0.004)
≤1 cm residual disease (27.3 vs
8.6 months, P = 0.031)
Fan [96] 2001 18 Ovary – immature
teratoma
3-year survival – 77.8 %
5-year survival – 55.6 %
10-year survival – 38.9 %
Not reported
Naik [97] 2000 37 Primary Ovary 11 months
2-year survival 23 %
5-year survival 9 %
Optimal surgery with residual
<2 cm (P = 0.0029) or <1 cm
(P = 0.0086)
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for non-colorectal, non-endocrine metastases per annum
did not exceed 17, whereas it rose to 70 during the
1990’s and 115 during the 2000’s [73].
In patients with colorectal and gut-associated endo-
crine tumors, the most likely mode of spread is via
the portal venous system. The majority of the pa-
tient’s tumor burden is thus confined to the abdo-
men [73], and 5-year survivals of 45-50 % are
routinely reported [87, 88]. By contrast, liver metas-
tases from gynaecological cancers reach the liver via
the systemic circulation, so other extra-abdominal
sites are likely to be involved, which has fostered
caution. Liver surgery should only be considered
when the metastatic disease is well controlled or
responding to systemic therapy, or when liver resec-
tion is part of the achievement of optimal cytoreduc-
tion for ovarian cancer [81, 82].
Lim et al. reported 16 patients who had parenchymal
liver metastases at the time of diagnosis with advanced
ovarian cancer [75]. Two patients (12.5 %) had
hematogenous metastases which were unresectable, while
14 (87.5 %) had parenchymal invasion from peritoneal
seeding, and were able to undergo complete resection.
These patients, who were officially FIGO stage IV, had the
same survival as patients with Stage IIIC disease.
A series of 26 patients undergoing hepatic resection for
metachronous metastases from ovarian cancer was re-
ported from the Mayo Clinic in 2003 [89]. The median
age of the patients was 62 years and a solitary liver lesion
was present in 17 patients (63.4 %). All patients had pelvic
and abdominal disease in addition to the liver metastases
and 42 % had a simultaneous bowel resection. Optimal
cytoreduction (<1 cm) was achieved in 21 patients
(80.7 %). Segmentectomy was required in 18 patients
(69.2 %) and right hepatectomy in 4 (15.4 %). There was
no serious morbidity or mortality from the surgery. There
was a significant survival advantage for patients whose
disease-free interval was >12 months (27.3 versus
5.7 months; p < 0.004)), and for those having optimal
cytoreduction (27.3 versus 8.6 months; p < 0.031)
In 2006, a multicentre French study reported the largest
series (1452) of patients who underwent hepatic resection
for non-colorectal, non-endocrine liver metastases [73].
Gynecologic cancer represented 126 cases (8.7 %), and al-
though the patients were highly selected, the results were
very satisfactory. Overall, the 5-year survival was 48 %. It
was 50 % for patients with ovarian cancer and 35 % for pa-
tients with a uterine primary [73]. For the 1452 patients
the 60-day operative mortality was 2.3 %.
Conclusions
From a review of the current literature, it is apparent
that surgery should play an increasing role in the man-
agement of patients with parenchymal metastases from
gynecological cancers to the lungs, brain or liver. Appro-
priate patient selection is critical, but surprisingly good
long-term survival results can be achieved for resection
of metastases from all three organs, in conjunction usu-
ally with the use of adjuvant radiation, chemotherapy or
hormonal therapy.
This requires the development of a committed, multi-
disciplinary team, working in a high volume tertiary cen-
ter, where the necessary infrastructure for postoperative
management is available. In these circumstances, post-
operative morbidity and mortality are low.
Ideally, patients should have metastatic disease confined
to the lungs, brain or liver, except in the case of a patient
with a chemosensitive ovarian cancer, where resection of
pulmonary or liver metastases may form part of the initial
cytoreductive surgical effort. A solitary metastasis is ideal,
but good results may be obtained with multiple metasta-
ses, as long as all macroscopic disease can be resected. A
disease-free interval of at least 12 months, and preferably
24 months is desirable, together with a satisfactory per-
formance status, and adequate functional reserve in the
organ being partially resected.
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Bristow [81] 1999 37 Primary Ovary Optimal extrahepatic and
hepatic resection – 50.1 months
Optimal extrahepatic resection




tumour – 7.6 months
Optimal extrahepatic
resection (P = 0.0001)
Elias [84] 1998 6 Not stated Gynecologic 5-year survival – 45 % Not reported
Chi [71] 1997 12 Recurrent Ovary – 58 %
Cervix – 17 %
Endometrium – 17 %
Fallopian tube – 1 8 %
27 months
(Median f/up 25 months,
range 8–94 months)
Not reported
OS overall survival, DFS disease-free survival, PFS progression-free survival
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